HK1247250A1 - 用於指導癌症治療的內容相關的診斷測試 - Google Patents

用於指導癌症治療的內容相關的診斷測試

Info

Publication number
HK1247250A1
HK1247250A1 HK18106406.5A HK18106406A HK1247250A1 HK 1247250 A1 HK1247250 A1 HK 1247250A1 HK 18106406 A HK18106406 A HK 18106406A HK 1247250 A1 HK1247250 A1 HK 1247250A1
Authority
HK
Hong Kong
Prior art keywords
cancer treatment
context dependent
diagnostics test
guiding cancer
guiding
Prior art date
Application number
HK18106406.5A
Other languages
English (en)
Inventor
Elisha J Dettman
Michael H Cardone
Original Assignee
Eutropics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eutropics Pharmaceuticals Inc filed Critical Eutropics Pharmaceuticals Inc
Publication of HK1247250A1 publication Critical patent/HK1247250A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Data Mining & Analysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
HK18106406.5A 2015-01-12 2018-05-17 用於指導癌症治療的內容相關的診斷測試 HK1247250A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562102499P 2015-01-12 2015-01-12
PCT/US2016/013003 WO2016115105A1 (en) 2015-01-12 2016-01-12 Context dependent diagnostics test for guiding cancer treatment

Publications (1)

Publication Number Publication Date
HK1247250A1 true HK1247250A1 (zh) 2018-09-21

Family

ID=56406281

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106406.5A HK1247250A1 (zh) 2015-01-12 2018-05-17 用於指導癌症治療的內容相關的診斷測試

Country Status (9)

Country Link
US (2) US10793915B2 (zh)
EP (1) EP3245301B1 (zh)
JP (1) JP6774951B2 (zh)
KR (1) KR20170126867A (zh)
CN (1) CN107406881B (zh)
AU (1) AU2016206882B2 (zh)
CA (1) CA2974240A1 (zh)
HK (1) HK1247250A1 (zh)
WO (1) WO2016115105A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
RU2759963C2 (ru) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Комбинированные терапии для лечения рака
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
EP3385715A1 (en) 2017-04-04 2018-10-10 Medizinische Hochschule Hannover Analytical process for predicting the therapeutic effect of bh3 mimetics
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
GB9422836D0 (en) * 1994-11-11 1995-01-04 Wainscoat James Monitoring malignant disease
AU4411097A (en) 1996-09-09 1998-03-26 Washington University Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US7064193B1 (en) 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
AU9402898A (en) 1997-09-26 1999-04-23 Washington University Cell death agonists
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
JP2002515267A (ja) 1998-05-18 2002-05-28 アポトーシス テクノロジー・インコーポレーテッド 抗アポトーシス遺伝子及び遺伝子産物に関する化合物、スクリーニング方法並びに用途
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
EP1104460A1 (en) 1998-08-19 2001-06-06 Washington University Modulation of apoptosis with bid
AU2001271426A1 (en) 2000-07-17 2002-01-30 Washington University Modulation of apoptosis
US20020177692A1 (en) 2001-04-16 2002-11-28 Myriad Genetics, Incorporated BCL-XL-interacting protein and use thereof
AU2002326980A1 (en) 2001-09-24 2003-04-07 Blood Center Research Foundation Method of modulating or examining ku70 levels in cells
WO2003057158A2 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
JP2006516383A (ja) 2002-09-09 2006-07-06 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３ペプチドおよびその使用方法
US7678893B2 (en) 2002-12-26 2010-03-16 Zakrytoe Aktsionernoe Obschestvo “Evrogen” Fluorescent proteins from Copepoda species and methods for using same
AU2004225439A1 (en) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
FR2855650B1 (fr) 2003-05-30 2006-03-03 Soitec Silicon On Insulator Substrats pour systemes contraints et procede de croissance cristalline sur un tel substrat
CN1302004C (zh) 2003-08-22 2007-02-28 浙江海正药业股份有限公司 一种阿糖胞苷的制备方法
CA2544223C (en) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8323987B2 (en) 2004-02-17 2012-12-04 The University Of North Carolina At Chapel Hill Modulation of epidermal growth factor heterodimer activity
EP2947160B1 (en) 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2008021484A2 (en) 2006-08-16 2008-02-21 Eutropics Pharmaceuticals Assay system to identify therapeutic agents
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US20090030005A1 (en) 2007-07-19 2009-01-29 Amgen Inc. Combinations for the treatment of cancer
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
WO2009137664A1 (en) 2008-05-07 2009-11-12 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of bcl-2 family and uses thereof
US20100015058A1 (en) 2008-06-25 2010-01-21 Stanford University Radiolabeled bbn-rgd heterodimers for cancer targeting
US9492449B2 (en) * 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102388151A (zh) 2009-02-11 2012-03-21 雅培制药有限公司 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物
CA2761777A1 (en) 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
US20130011393A1 (en) 2010-01-12 2013-01-10 Johnathan Mark Lancaster Bad pathway gene signature
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US9012215B2 (en) * 2011-09-22 2015-04-21 The Johns Hopkins University Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
US20150110779A1 (en) 2012-03-15 2015-04-23 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
EP2847592A4 (en) 2012-05-10 2016-05-04 Eutropics Pharmaceuticals Inc SURROGATE FUNCTIONAL DIAGNOSTIC TEST FOR CANCER
EP2898327A1 (en) 2012-09-19 2015-07-29 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
US10739333B2 (en) 2013-09-19 2020-08-11 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
EP3063302B1 (en) 2013-10-30 2019-12-04 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
JP6814745B2 (ja) 2015-04-27 2021-01-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ダイナミックｂｈ３プロファイリングを使用する毒性を評価するための組成物および方法

Also Published As

Publication number Publication date
KR20170126867A (ko) 2017-11-20
US20200392585A1 (en) 2020-12-17
US20180340229A1 (en) 2018-11-29
EP3245301B1 (en) 2020-11-11
EP3245301A4 (en) 2018-11-21
US10793915B2 (en) 2020-10-06
CN107406881A (zh) 2017-11-28
WO2016115105A1 (en) 2016-07-21
JP6774951B2 (ja) 2020-11-04
CN107406881B (zh) 2021-05-25
AU2016206882B2 (en) 2022-03-10
AU2016206882A1 (en) 2017-07-27
JP2018503092A (ja) 2018-02-01
EP3245301A1 (en) 2017-11-22
CA2974240A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
HK1251407A1 (zh) 治療癌症的方法
ZA201706616B (en) Method for treating cancer
HK1247250A1 (zh) 用於指導癌症治療的內容相關的診斷測試
IL304252A (en) Cancer treatment methods
IL289947A (en) A method for treating cancer
IL257691A (en) A method for treating cancer
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
GB201513436D0 (en) Apparatus for performing fracture reduction
IL256139B (en) Bladder cancer diagnosis methods
HK1250944A1 (zh) 用於治療癌症的方法
HK1248135A1 (zh) 用於治療癌症的聯合方法
HK1250942A1 (zh) 用於治療癌症的方法
HK1250943A1 (zh) 用於治療癌症的方法
GB2556352B (en) Guide apparatus
SG10201508795XA (en) Method for treating cancer
GB201505877D0 (en) Radiotherapy apparatus
GB201506625D0 (en) Guide apparatus
GB2542329B (en) Analysis Apparatus
GB2535170B (en) Radiotherapy apparatus
GB201518501D0 (en) Symphylit an apparatus for symphysiotomy